IngentaConnect alpha7 Nicotinic Receptor Agonists as Potential Therapeutic Drugs...

Authors: Hashimoto, Kenji¹; Koike, Kaori¹; Shimizu, Eiji¹; Iyo, Masaomi¹

Source: Current Medicinal Chemistry - Central Nervous System Agents, Volume 5, Number 3, September 2005 , pp. 171-184(14)

Publisher: Bentham Science Publishers

Abstract:

Deficient inhibitory processing of the P50 auditory evoked potential is a measurable marker observed in schizophrenia. Several lines of evidence suggest that agr

7 nicotinic receptors ( agr

7 nAChRs) play a critical role in P50 auditory sensory gating in the human brain. Similar to schizophrenic patients, DBA/2 mice spontaneously exhibit a deficit in inhibitory processing of the P20-N40 auditory evoked potential, which is a rodent analogue of the human P50 auditory evoked potential. Agonists at agr

7 nAChRs improve deficient inhibitory processing of the P20-N40 auditory gating potential in DBA/2 mice. In this article, we review the role of agr

7 nAChRs in the pathophysiology of schizophrenia, and agr

7 nAChR agonists and indirect agonists (5-hydroxytryptamine-3 (5-HT3) receptor antagonists, positive allosteric modulators (galantamine, 5-hydroxyindole, PNU-120596), FK960, FR236924) at agr

7 nAChRs as potential therapeutic drugs for the treatment of schizophrenia. In addition, we also discuss the role of kynurenic acid as an endogenous antagonist of agr

7 nAChRs in brain.

Keywords: a nicotinic receptors; auditory gating; sensory gating; cognition; schizophrenia

Document Type: Review article

DOI: 10.2174/1568015054863828

Affiliations: 1: Dr. Kenji Hashimoto, Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba 260-8670, Japan.

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax Refund Policy

7 Nicotinic Receptor Agonists as Potential Therapeutic Drugs for Schizophrenia